The trial’s primary efficacy endpoint is AF burden, which refers to the percentage of time a participant is in AF.

Acesion Pharma has begun enrolling patients into a phase 2 clinical trial of AP31969, its novel oral SK ion channel inhibitor being developed for rhythm control in atrial fibrillation.

Acesion Pharma ("Acesion" or "the Company"), a biotech company pioneering treatments for atrial fibrillation ("AF"), the most common cardiac arrhythmia, today announces enrolment of the first patients ...

The SNS records neural activity from 60 channels across four brain regions--an order-of-magnitude increase over commercially available devices. The NeuroPace RNS system, FDA-cleared for epilepsy, ...

Nia Therapeutics announced the publication of the first in vivo validation of its wireless, implantable brain-computer ...

Scientists from Turkey have designed a next-generation implantable biosensor using genetically engineered E. coli for molecular-level monitoring within the body that runs on its own, wirelessly, with ...

Neal has more than 20 years of experience in financial and business journalism covering retail investing, airlines, pharmaceuticals, healthcare, sustainability, technology, and retail. He has worked ...